It is worthy of note that achieving a pCR after receiving neoadjuvant chemotherapy provides important prognostic information and is considered a surrogate endpoint for event-free survival in ERα− or triple negative BC.37–39 In contrast, in ERα+ and HER2+ BC, the event-free survival is merely determined by the administration of targeting therapy: either endocrine or Herceptin therapy. This evidence concerns the gene ERBB2 and breast cancer.